

## **Associations between early in-hospital medications and the development of delirium in patients with stroke**

Sophia L. Ryan MD,<sup>1,2</sup> Xiu Liu MS,<sup>1,3</sup> Vanessa McKenna RN,<sup>1</sup> Manohar Ghanta MS,<sup>1</sup> Carlos Muniz MD MSc,<sup>1,4</sup> Rachel Renwick, PharmD,<sup>1</sup> M. Brandon Westover MD PhD,<sup>1,5</sup> Eyal Y. Kimchi MD PhD<sup>1,6</sup>

1. Department of Neurology, Massachusetts General Hospital
2. Department of Neurology, Mount Sinai Medical Center
3. Lawrence Center for Quality and Safety, Massachusetts General Hospital
4. Department of Neurology, SUNY Upstate Medical University
5. Department of Neurology, Beth Israel Deaconess Medical Center
6. Department of Neurology, Northwestern University

Short Title: In-hospital medications and delirium in stroke

Emails:

[sophialryan@gmail.com](mailto:sophialryan@gmail.com), [xliu0@mgh.harvard.edu](mailto:xliu0@mgh.harvard.edu), [vmckenna@partners.org](mailto:vmckenna@partners.org), [mghanta@mgh.harvard.edu](mailto:mghanta@mgh.harvard.edu),  
[munizc@upstate.edu](mailto:munizc@upstate.edu), [recenwick@gmail.com](mailto:recenwick@gmail.com), [mwestove@bidmc.harvard.edu](mailto:mwestove@bidmc.harvard.edu),  
[eyal.kimchi@northwestern.edu](mailto:eyal.kimchi@northwestern.edu)

Corresponding Author:

Eyal Y. Kimchi, MD, PhD

Keywords:

stroke; delirium; medications; polypharmacy

## ABSTRACT

**Objectives:** Patients hospitalized with stroke develop delirium at higher rates than general hospitalized patients. While several medications are associated with existing delirium, it is unknown whether early medication exposures are associated with subsequent delirium in patients with stroke. Additionally, it is unknown whether delirium identification is associated with changes in the prescription of these medications.

**Materials and Methods:** We conducted a retrospective cohort study of patients admitted to a comprehensive stroke center, who were assessed for delirium by trained nursing staff during clinical care. We analyzed exposures to multiple medication classes in the first 48 hours of admission, and compared them between patients who developed delirium >48 hours after admission and those who never developed delirium. Statistical analysis was performed using univariate testing and multivariable logistic regression.

**Results:** 1,710 unique patients were included in the cohort, of whom 471 (27.5%) developed delirium >48 hours after admission. Delirium was associated with prior exposure to antipsychotics, sedatives, opiates, and antimicrobials, even after accounting for several clinical covariates. Usage of these medications decreased in the 48 hours following delirium identification, except for atypical antipsychotics, whose use increased. Other medication classes such as steroids, benzodiazepines, and sleep aids were not initially associated with subsequent delirium, but prescription patterns still changed after delirium identification.

**Conclusions:** Early exposure to multiple medication classes is associated with the subsequent development of delirium in patients with stroke. Additionally, prescription patterns changed following delirium identification, suggesting that these medication classes may be modifiable targets for future delirium prevention strategies.

**Key Words:** stroke; delirium; medications; polypharmacy

**140-character message:** Early exposure to specific medication classes is associated with delirium in patients with stroke & may be targets for future prevention.

@SophiaLRyan, @ekimchi, @MGHNeurology, @MSHSNeurology, @NMNeurology

## INTRODUCTION

Delirium is a disorder of attention and awareness that is common among patients with stroke and is associated with a longer length of stay, increased risk of readmission, and death.<sup>1-3</sup> Patients with stroke are particularly vulnerable to delirium compared to the general hospitalized population (13-48% occurrence in patients with stroke, compared to 10-25% occurrence among the general hospital population).<sup>1</sup> Given that delirium is often incident, arising after hospitalization,<sup>4</sup> it is important to identify factors that may affect or anticipate its development.<sup>5</sup> Delirium can be prevented through nonpharmacologic interventions in general medical<sup>6</sup> and general neurology<sup>7</sup> inpatients, however, it is less clear whether such interventions can prevent or treat delirium in patients with stroke.<sup>8-10</sup> The prevention and management of delirium remain an important challenge in the care of hospitalized patients with stroke.

Delirium has many potential contributing factors, both non-modifiable factors, such as age and cognitive impairment,<sup>11-16</sup> and potentially modifiable factors, including medications.<sup>17-19</sup> In addition to polypharmacy, certain classes of medications are thought to be deliriogenic including sedatives,<sup>20</sup> antimicrobials,<sup>21,22</sup> opiates,<sup>23</sup> antiepileptics,<sup>24</sup> medications for the treatment of Parkinson's disease,<sup>25-27</sup> steroids<sup>28,29</sup>, benzodiazepines,<sup>30</sup> anticholinergics,<sup>31,32</sup> antiemetics,<sup>33</sup> mood stabilizers<sup>34</sup> and muscle relaxants.<sup>35</sup> Avoidance of potentially deliriogenic medications, where clinically appropriate, may represent an opportunity for delirium prevention.

While associations between in-hospital medications and delirium have been examined in older patients,<sup>36,37</sup> ICU patients,<sup>38,39</sup> and post-operative patients,<sup>30</sup> it is not currently known how medications administered early in a hospitalization impact the subsequent development of delirium in patients with stroke. Additionally, there is no literature describing to what extent the administration of such medications may be clinically modifiable once delirium has occurred. We therefore conducted a

retrospective cohort study to determine which medications administered in the first 48 hours of hospitalization predicted the subsequent development of delirium in patients with stroke. Additionally, we sought to characterize how prescribing patterns changed after delirium was identified.

## **METHODS**

### **Data availability**

Anonymized data not published within this article will be made available by request from qualified investigators.

### **Patient population**

We performed a retrospective cohort study of all patients admitted to our comprehensive stroke center with acute neurovascular disease based on ICD10 coding, including ischemic or hemorrhagic stroke, between January 2017 and April 2019. Given that we were interested in the effect of medications administered within the first 48 hours of hospitalization on the subsequent development of delirium, only those with a hospital stay of greater than 48 hours and a recorded delirium screen were included. We excluded patients who screened positive for delirium in the first 48 hours and those who did not have any delirium screen recorded. Only one admission was included per patient. The sample size was determined by the number of admissions during this time as a sample of convenience. Race, ethnicity, marital status, English speaking and insurance payor were all obtained from an internal quality improvement database.

### **Clinical data**

Delirium assessments were extracted from the electronic medical record, in addition to patient demographics, baseline characteristics, medication administration, and clinical outcomes. When available, the NIH stroke scale (NIHSS) was also extracted. We used admission nursing screens to determine rates of visual and hearing impairment, denture use, dependence in activities of daily living, and memory impairment. Potentially hazardous alcohol use was determined by either an Audit C score on admission suggestive of alcohol overuse<sup>40</sup> or use of a Clinical Institute Withdrawal Assessment (CIWA) scale.<sup>41</sup> We also collected internal administrative data identify neurovascular intervention. Relative costs were determined from a hospital administrative database in relative units, as per hospital administrative policy.

## **Delirium assessment**

The primary outcome of this study was the development of delirium 48 hours or more after admission. Delirium was assessed by trained neurology nurses once per shift (twice daily) as part of routine clinical care, using the CAM-ICU in the Intensive Care Unit<sup>42,43</sup> and a Confusion Assessment Method (CAM) framework on the wards<sup>44</sup>. CAM-based algorithms for delirium identification have been validated in various patient populations, including the general hospital population<sup>44,45</sup> and patients with acute stroke<sup>2,43,46</sup>.

Nursing staff were trained to perform assessments as part of a departmental quality initiative through a combination of in-person didactics, in-service sessions, online training, and targeted feedback including ongoing discussions from nurse supervisors. Nurses were specifically trained regarding CAM administration in the neurosciences population, including in the setting of aphasia and dementia. Staff could discuss complex or uncertain cases during daily interdisciplinary group rounds, where formalized interdisciplinary checklists prompted the identification of each patient's delirium status.

Patients were stratified by their delirium status into those who never had a positive delirium assessment and those who first screened positive >48 hours after admission. We excluded patients who developed delirium within the first 48 hours of hospitalization, in order to examine the importance of potentially delirious medications prior to delirium onset.

## **Medication data**

The main exposures in this study were selected medication classes. Based on the literature and *a priori* clinical knowledge, we selected the following potentially deliriogenic medication classes for study: sedatives,<sup>20</sup> antimicrobials,<sup>21,22</sup> opiates,<sup>23</sup> antiepileptics,<sup>24</sup> medications for the treatment of Parkinson's disease,<sup>25-27</sup> steroids<sup>28,29</sup>, benzodiazepines,<sup>30</sup> anticholinergics,<sup>31,32</sup> antiemetics,<sup>33</sup> mood stabilizers<sup>34</sup> and

muscle relaxants.<sup>35</sup> We also looked at sleep aids, as these are often used to manage the disrupted sleep-wake cycles of delirious patients,<sup>47,48</sup> stimulants, which may cause hyperactive delirium and are sometimes used off-label for the treatment of hypoactive delirium,<sup>49-51</sup> and cholinesterase inhibitors and memantine,<sup>52,53</sup> which have been trialed in the prevention and treatment of delirium although data has been mixed. Finally, we also examined antipsychotic medications, which are frequently used off-label in the management of delirium but may also be potentially deliriogenic.<sup>54,55</sup>

Anticholinergic medications were defined according to the American Geriatric Society's 2019 Beers criteria.<sup>19</sup> We restricted each medication to appear in only a single therapeutic class based on clinical knowledge of common usage (e.g. quetiapine as an atypical antipsychotic, rather than also an anticholinergic). Medications in each class are listed in Supplemental Table S1. Lastly, when medications were administered via routes with minimal systemic absorption they were removed (i.e. topical, inhaled, eye or ear drops, etc).

### **Statistical analysis**

Descriptive analyses were used to summarize the characteristics of patients who did and did not develop delirium in terms of (1) demographic and baseline characteristics; (2) clinical characteristics related to their hospitalization; (3) clinical outcomes. Medians and interquartile ranges were presented for continuous variables, and percentages were calculated for categorical variables.

We compared medication class exposures during the first 48 hours of admission between patients who did and did not developed delirium. Due to variability in the medications used, including doses and routes of administration, as well as a lack of consensus on dose conversion for several classes, we evaluated medication exposures rather than doses. Chi-square or Fisher's exact tests were used for categorical variables and the Wilcoxon rank sum test was used for continuous variables.



Based on the univariate analysis and *a priori* knowledge, we built a multivariable logistic regression model controlling for potential confounders and significant predictors of delirium (including hemorrhagic stroke, ventilator status during the first 48 hours, age, and sex) along with exposures to univariate statistically significant medications. Ventilator status instead of ICU status was utilized to control for its strong association with sedatives. Risk ratios and 95% confidence interval were presented in the multivariable regression analysis

Finally, among those patients who developed delirium, we compared the change in proportions of patients receiving potentially deliriogenic medications in the 48 hours before and after delirium identification, using McNemar's test. A p-value < 0.05 was considered statistically significant in all analyses. Descriptive statistics were performed using MATLAB (R2018b, MathWorks), and inferential statistics were performed using SAS software, version 9.4 (SAS Institute).

### **Approval**

This study was approved by the Institutional Review Board at Massachusetts General Hospital (Boston).

## **RESULTS**

### **Patient demographics and baseline characteristics**

12,228 admissions to the clinical neuroscience wards occurred during the study period, of whom 1,710 unique patients with acute neurovascular diagnoses were included for analysis (Figure 1). Of these, 1,020 patients presented with primarily ischemic stroke and 649 patients with primarily intracranial hemorrhage. The remaining 41 patients had other symptomatic neurovascular compromise (for example, MRI negative transient ischemic attack). Delirium developed 48 hours or more after admission in 27.5% of patients (471/1710; Table 1). Patients who developed delirium 48 hours or more into their hospitalization, as compared to those who did not develop delirium, tended to be older, have Medicare or Medicaid insurance, have pre-existing hearing and memory impairment, and required assistance with more activities of daily living (ADLs). Sex, ethnicity, race, and English fluency were similar between patients with and without delirium. Patients who were not assessed for delirium during their hospitalization tended to be younger and have shorter lengths of stay (Supplementary Table S2).

### **Acute clinical characteristics**

Patients who developed delirium were more likely to have intracranial hemorrhage and less likely to have ischemic stroke than patients who did not develop delirium (Table 1). Median NIH stroke scale scores among ischemic stroke patients were higher for patients who developed delirium. Patients who developed delirium were also more likely to have received tissue plasminogen activator and neurovascular intervention, and more likely to have been in the ICU during the first 48 hours of admission and to have been on a ventilator. Patients who developed delirium were also more likely to receive physical restraints and urinary catheters within the first 48 hours of hospitalization.

### **Clinical outcomes**

Clinical outcomes were worse in patients who developed delirium during their hospitalization (Table 1), including longer length of stay, higher rates of 30-day readmission, higher in-hospital mortality, and increased discharge to facilities rather than home. The relative total cost of hospitalization was more than two times higher among patients who developed delirium.

### **Medications classes significantly associated with delirium**

Patients who developed delirium received more unique medications in the first 48 hours after admission (median 24, IQR 18-29) compared to those who never developed delirium (median 18, IQR 12-23,  $p < 0.0001$ ).

#### **Antipsychotics**

Patients who developed delirium were more likely to have received early antipsychotics (Table 2). Haloperidol was the most commonly prescribed typical antipsychotic and quetiapine the most commonly prescribed atypical antipsychotic. Both typical and atypical antipsychotics were significantly associated with delirium, even in the multivariable model (Table 3). Following delirium identification, there was a significant reduction in the use of typical antipsychotics, but a significant increase in the use of atypical antipsychotics (Table 4).

#### **Sedatives**

Patients who developed delirium were more likely to have received early sedatives. Propofol and dexmedetomidine were the most commonly prescribed sedatives. In the multivariable model, sedatives remained significantly associated with delirium, even accounting for ventilation status. Additionally, the association between sedatives and delirium remained present even when performing a stratified analysis within just ventilated patients (Supplementary Table S3). Following delirium identification, there was a significant reduction in the use of sedatives.

### **Cholinesterase Inhibitors and Memantine**

Patients who developed delirium were more likely to have received early cholinesterase inhibitors or memantine. However, only 1.8% of patients received such medications in this time frame (31/1710). Donepezil and memantine were the most commonly prescribed medications in this group. However, the association was not significant in the multivariable model and there was no significant change in administration after delirium identification.

### **Antimicrobials**

Patients who developed delirium were more likely to have received early antimicrobials. The most commonly prescribed antimicrobials were cefazolin, vancomycin, and ciprofloxacin. In the multivariable model, antimicrobials remained significantly associated with delirium. Following delirium identification, there was a significant reduction in the use of antimicrobials.

### **Opiates**

Patients who developed delirium were more likely to have received early opiates. Opiates were the most commonly prescribed medication class among all patients (475/1710, 27.8%), and oxycodone and hydromorphone were the most commonly prescribed opiates. In the multivariable model, opiates remained significantly associated with delirium. Following delirium identification, there was a significant reduction in opiate administration.

### **Antiepileptics**

Patients who developed delirium were more likely to have received early antiepileptics. Levetiracetam was the most commonly prescribed antiepileptic medication. However, the association was not significant in the multivariable model. Following delirium identification, there was a significant reduction in antiepileptic administration.

## **Medications not significantly associated with delirium**

### **Anticholinergics**

Oxybutynin was the most commonly prescribed anticholinergic medication. Anticholinergics were not significantly associated with the development of delirium. Following delirium identification there was no significant change in anticholinergic administration.

### **Steroids**

Dexamethasone was the most commonly prescribed steroid. Steroids were not significantly associated with the development of delirium. Following delirium identification, however, there was a significant reduction in steroid administration.

### **Benzodiazepines:**

Lorazepam was the most commonly prescribed benzodiazepine. Benzodiazepines were not significantly associated with the development of delirium. Following delirium identification, however, there was a significant reduction in benzodiazepine administration.

### **Stimulants**

Only 1.6% of patients (28/1710) received stimulants, the most commonly prescribed of which was amantadine. Stimulants were not significantly associated with the development of delirium. Following delirium identification, however, there was a significant increase in stimulant administration.

### **Sleep Aids**

Sleep aids were not significantly associated with the development of delirium in the univariate analysis. Melatonin and trazodone were the most common sleep aids prescribed. Following delirium identification, however, there was a significant increase in sleep aid administration.

## DISCUSSION

Delirium is a complex, multifactorial syndrome that is common and associated with poor prognosis among patients with stroke, driving strong interest in identifying potentially modifiable risk factors to help prevent or treat it. In patients admitted to a comprehensive stroke center, several classes of medications administered in the first 48 hours were associated with the subsequent development of delirium, including antipsychotics, sedatives, opiates, and antimicrobials. Establishing a temporal context with medication administration preceding delirium is an understudied but important step to understanding the clinical significance of medications associated with delirium, as identified previously in other patient populations.

As in other studies, the association between a medication class and delirium is likely to be complex. For example, antipsychotics could be potentially deliriogenic by impairing cognition and movement.<sup>56-58</sup> However, the association may also reflect confounding by indication, as anti-psychotics are often used off-label for the treatment of agitation, which can be a premonitory symptom of delirium. Prospective, randomized controlled trials have provided equivocal evidence on the utility of anti-psychotics for delirium, but meta-analyses suggest their routine use should be avoided.<sup>59,60</sup> While the use of anti-psychotics specifically for agitation is hard to track retrospectively, for the use of sedatives we were able to track ventilation status. Intriguingly, sedatives remained associated with delirium even after accounting for ventilation status, supporting the importance of interrupting sedation as early and as often as clinically appropriate.<sup>20</sup>

Opiates are also potentially deliriogenic,<sup>23</sup> and in our data an association with delirium was maintained even after controlling for ventilator status and intracerebral hemorrhage. While some opiates, like meperidine, are thought to be highly deliriogenic, others, like hydromorphone, are perhaps less so.<sup>23</sup> Prescribing practices within our institution did not yield sufficient power to detect differences within

classes. The results, however, suggest that providers should prescribe opiates as a class cautiously in stroke patients at high risk for delirium. The decision is admittedly complex in that pain may also be deliriogenic,<sup>61</sup> and further research is needed to balance these concerns.

Early antimicrobials were associated with the subsequent development of delirium. Antimicrobials are prescribed to treat infections, which may be deliriogenic. However, it is increasingly recognized that antimicrobials can have significant neuropsychiatric side effects, including delirium or encephalopathy.<sup>21,22,62</sup> While antimicrobial administration may at times be critical, there is also the potential for misuse or overuse. Even for routine clinical concerns, such as aspiration<sup>63</sup> or asymptomatic bacteriuria, there is heterogeneity and limited data to support the use of routine antibiotics.<sup>64,65</sup> More surprisingly, we observed that following delirium identification antimicrobials were actually deprescribed, suggesting that they were not strictly necessary. We could not determine if the specific reason for deprescribing was identification of delirium in this retrospective study. This data suggests the need for a prospective study of antibiotic practices in the setting of delirium with standardized definitions of infection, potentially enabling possible future randomized controlled trials comparing high vs. low thresholds for antibiotic treatment in this patient population.

Among pertinent negative results in our study was the lack of a clear association between anticholinergic medications and subsequent delirium. Anticholinergic medications are a class for which there seems to be plausible pathophysiologic rationale for delirium precipitation.<sup>66</sup> However, the association in prior literature has been inconsistent.<sup>31,32,67</sup> Notably, many medications with anticholinergic properties also fall into other classes, for example olanzapine is an anti-psychotic that is sometimes thought to have anticholinergic properties.<sup>19</sup> We retained such medications in their most recognized therapeutic class to reflect prescribing indications.

At our comprehensive stroke center, there was significant deprescribing of potentially deliriogenic medications after delirium identification, with a smaller proportion of patients receiving benzodiazepines, steroids, opiates, anticholinergics, and sedatives after delirium identification. There was also an increase in sleep aid administration after delirium identification, likely reflecting attempts to regulate sleep-wake cycles. These findings suggest not only an awareness of delirium status on the part of the clinical staff but also efforts to reduce deliriogenic medication exposure after delirium has been identified. Whether deprescribing effectively treats delirium or whether it would be more effective with earlier implementation remains unclear and requires future study. We also observed what is likely off-label use of antipsychotics for delirium management, with a decrease in typical antipsychotics but an increase in atypical antipsychotics after delirium identification. Given that some delirium symptoms such as agitation may present safety concerns or barriers to transfer to rehabilitation facilities, delirium symptom control will likely remain an ongoing clinical concern in this patient population.

There are several limitations to our study. This study was performed at a single large, academic comprehensive stroke center. Although our center reflects the varying practices of many vascular neurologists, the results may not generalize to other settings. Approximately 1/3 of patients were not assessed for delirium, pointing to the need for ongoing efforts to improve clinical delirium assessment. However, patients not assessed tended to be younger and have shorter stays, suggesting that rates of delirium would have been lower in this group. Additionally, we specifically excluded patients who screened positive for delirium within the first 48 hours in order to clarify the temporal relationship between medications and the development of delirium, as confounding by indication is likelier when delirium presence and medication use are concurrent. More than three quarters of patients had their first positive delirium assessment recorded after 72 hours, creating at least a 24-hour buffer for most patients between early medication administration and subsequent development of delirium. While it is unknown whether the pathophysiology of hospital acquired or incident delirium differs from delirium already prevalent on admission, incident delirium as studied here is associated with longer length of stay.<sup>68,69</sup>



Given the retrospective nature of the study, some covariate data was missing, for example knowledge of the baseline cognitive status of some patients, and home medications. However, most of the medications identified are not common outpatient medications. Lastly, medications were grouped by classes for sufficient statistical power. Larger studies may help identify specific medications within such classes associated with higher or lower risks of delirium.

## **Conclusion**

While several medications classes have been associated with concurrent delirium in various patient populations, it is unknown whether early administration of these medications are associated with subsequent delirium in patients with stroke. In a comprehensive stroke center, opiate, sedative, antimicrobial, and antipsychotic exposure were all significantly associated with the subsequent development of delirium when controlling for confounding. Additionally, there was significant deprescribing of several potentially deliriogenic medication classes in the setting of delirium identification, suggesting modifiable targets for future delirium prevention strategies in patients with stroke.

## **Acknowledgements**

The authors acknowledge the efforts of the Massachusetts General Hospital Neuroscience Delirium Task Force and neurology nurses.

## **Sources of Funding**

MBW was supported by the Glenn Foundation for Medical Research and American Federation for Aging Research (Breakthroughs in Gerontology Grant); American Academy of Sleep Medicine (AASM Foundation Strategic Research Award); NIH (R01NS102190, R01NS102574, R01NS107291, RF1AG064312, R01AG062989, R01AG073410); and NSF (SCH-2014431). EYK was supported by a K08-MH116135. This work was conducted with support from Harvard Catalyst (NIH UL 1TR002541) and financial contributions from Harvard University and its affiliated academic healthcare centers.

## **Disclosures**

MBW is a co-founder of Beacon Biosignals, which played no role in this work. This work was completed while RR was employed by Massachusetts General Hospital, RR is now an employee of UCB Pharma, which played no role in this work. Other authors report no disclosures relevant to the manuscript.

## **Supplemental Material**

Supplementary Tables S1–S3

## References

1. Shi Q, Presutti R, Selchen D, Saposnik G. Delirium in Acute Stroke: A Systematic Review and Meta-Analysis. *Stroke*. 2012;43(3):645-649. doi:10.1161/STROKEAHA.111.643726
2. Oldenbeuving AW, de Kort PLM, Jansen BPW, Algra A, Kappelle LJ, Roks G. Delirium in the acute phase after stroke: Incidence, risk factors, and outcome. *Neurology*. 2011;76(11):993-999. doi:10.1212/WNL.0b013e318210411f
3. McManus J, Pathansali R, Hassan H, et al. The course of delirium in acute stroke. *Age Ageing*. 2009;38(4):385-389. doi:10.1093/ageing/afp038
4. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. *Age Ageing*. 2006;35(4):350-364. doi:10.1093/ageing/afl005
5. Rhee JY, Colman MA, Mendu M, et al. Associations Between Stroke Localization and Delirium: A Systematic Review and Meta-Analysis. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc*. 2022;31(3):106270. doi:10.1016/j.jstrokecerebrovasdis.2021.106270
6. Inouye SK, Bogardus ST, Charpentier PA, et al. A Multicomponent Intervention to Prevent Delirium in Hospitalized Older Patients. *N Engl J Med*. 1999;340(9):669-676. doi:10.1056/NEJM199903043400901
7. Brown EG, Josephson SA, Anderson N, Reid M, Lee M, Douglas VC. Evaluation of a multicomponent pathway to address inpatient delirium on a neurosciences ward. *BMC Health Serv Res*. 2018;18(1):106. doi:10.1186/s12913-018-2906-3
8. Nydahl P, Baumgarte F, Berg D, et al. Delirium on stroke units: a prospective, multicentric quality-improvement project. *J Neurol*. Published online February 14, 2022. doi:10.1007/s00415-022-11000-6
9. Rice KL, Bennett MJ, Berger L, et al. A Pilot Randomized Controlled Trial of the Feasibility of a Multicomponent Delirium Prevention Intervention Versus Usual Care in Acute Stroke. *J Cardiovasc Nurs*. 2017;32(1):E1-E10. doi:10.1097/JCN.0000000000000356
10. Song J, Lee M, Jung D. The Effects of Delirium Prevention Guidelines on Elderly Stroke Patients. *Clin Nurs Res*. 2018;27(8):967-983. doi:10.1177/1054773817721400
11. Morandi A, McCurley J, Vasilevskis EE, et al. Tools to Detect Delirium Superimposed on Dementia: A Systematic Review. *J Am Geriatr Soc*. 2012;60(11):2005-2013. doi:10.1111/j.1532-5415.2012.04199.x
12. Morandi A, Davis D, Bellelli G, et al. The Diagnosis of Delirium Superimposed on Dementia: An Emerging Challenge. *J Am Med Dir Assoc*. 2017;18(1):12-18. doi:10.1016/j.jamda.2016.07.014
13. Jones RN, Fong TG, Metzger E, et al. Aging, Brain Disease, and Reserve: Implications for Delirium. *Am J Geriatr Psychiatry*. 2010;18(2):117-127. doi:10.1097/JGP.0b013e3181b972e8
14. Alvarez-Perez FJ, Paiva F. Prevalence and Risk Factors for Delirium in Acute Stroke Patients. A Retrospective 5-Years Clinical Series. *J Stroke Cerebrovasc Dis*. 2017;26(3):567-573.
15. Caeiro L, Ferro JM, Albuquerque R, Figueira ML. Delirium in the first days of acute stroke. *J Neurol*. 2004;251(2):171-178. doi:10.1007/s00415-004-0294-6
16. Ding G, Hua S, Chen J, Yang S, Xie R. Does cognitive decline/dementia increase Delirium risk after stroke? *Psychogeriatr Off J Jpn Psychogeriatr Soc*. 2021;21(4):605-611. doi:10.1111/psyg.12720

17. Gaudreau JD, Gagnon P, Roy MA, Harel F, Tremblay A. Association Between Psychoactive Medications and Delirium in Hospitalized Patients: A Critical Review. *Psychosomatics*. 2005;46(4):302-316. doi:10.1176/appi.psy.46.4.302
18. Sieber F, Neufeld KJ, Gottschalk A, et al. Depth of sedation as an interventional target to reduce postoperative delirium: mortality and functional outcomes of the Strategy to Reduce the Incidence of Postoperative Delirium in Elderly Patients randomised clinical trial. *BJA Br J Anaesth*. 2019;122(4):480-489. doi:10.1016/j.bja.2018.12.021
19. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults: 2019 AGS BEERS CRITERIA® UPDATE EXPERT PANEL. *J Am Geriatr Soc*. 2019;67(4):674-694. doi:10.1111/jgs.15767
20. Reade MC, Finfer S. Sedation and Delirium in the Intensive Care Unit. *N Engl J Med*. 2014;370(5):444-454. doi:10.1056/NEJMra1208705
21. Bhattacharyya S. Antibiotic-associated encephalopathy. Published online 2016:11.
22. Bangert MK, Hasbun R. Neurological and Psychiatric Adverse Effects of Antimicrobials. *CNS Drugs*. 2019;33(8):727-753. doi:10.1007/s40263-019-00649-9
23. Swart LM, van der Zanden V, Spies PE, de Rooij SE, van Munster BC. The Comparative Risk of Delirium with Different Opioids: A Systematic Review. *Drugs Aging*. 2017;34(6):437-443. doi:10.1007/s40266-017-0455-9
24. Bohlken J, Kostev K. Prevalence and risk factors for delirium diagnosis in patients followed in general practices in Germany. *Int Psychogeriatr*. 2018;30(4):511-518. doi:10.1017/S1041610217002587
25. Serrano-Dueñas M, Bleda MJ. Delirium in Parkinson's disease patients. A five-year follow-up study. *Parkinsonism Relat Disord*. 2005;11(6):387-392. doi:10.1016/j.parkreldis.2005.05.002
26. Young BK, Camicioli R, Ganzini L. Neuropsychiatric Adverse Effects of Antiparkinsonian Drugs. *Drugs Aging*. 1997;10(5):367-383. doi:10.2165/00002512-199710050-00005
27. Ebersbach G, Ip CW, Klebe S, et al. Management of delirium in Parkinson's disease. *J Neural Transm*. 2019;126(7):905-912. doi:10.1007/s00702-019-01980-7
28. Koh YI, Choi IS, Shin IS, Hong SN, Kim YK, Sim MK. Steroid - induced delirium in a patient with asthma / report of one case. *Korean J Intern Med*. 2002;17(2):150-152. doi:10.3904/kjim.2002.17.2.150
29. The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. *Clin Pharmacol Ther*. 1972;13(5part1):694-698. doi:10.1002/cpt1972135part1694
30. Marcantonio ER, Juarez G, Goldman L, et al. The Relationship of Postoperative Delirium With Psychoactive Medications. :5.
31. Gustafson Y, Olsson T, Eriksson S, Asplund K, Bucht G. Acute Confusional States (Delirium) in Stroke Patients. *Cerebrovasc Dis*. 1991;1:257-264.
32. Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association Between Prescribing of Anticholinergic Medications and Incident Delirium: A Cohort Study. *J Am Geriatr Soc*. 2011;59:S277-S281. doi:10.1111/j.1532-5415.2011.03676.x
33. Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. *Aust Prescr*. 2020;43(2):49-56. doi:10.18773/austprescr.2020.011


34. Alagiakrishnan K. An approach to drug induced delirium in the elderly. *Postgrad Med J*. 2004;80(945):388-393. doi:10.1136/pgmj.2003.017236
35. Whitlock EL, Vannucci A, Avidan MS. POSTOPERATIVE DELIRIUM. Published online 2013:12.
36. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *Lancet*. 2014;383:911-922.
37. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Élie M. Use of Medications With Anticholinergic Effect Predicts Clinical Severity of Delirium Symptoms in Older Medical Inpatients. *Arch Intern Med*. 2001;161(8):1099. doi:10.1001/archinte.161.8.1099
38. Cui Y, Li G, Cao R, Luan L, Kla KM. The effect of perioperative anesthetics for prevention of postoperative delirium on general anesthesia\_ A network meta-analysis. *J Clin Anesth*. 2020;59:89-98. doi:10.1016/j.jclinane.2019.06.028
39. Dale CR, Kannas DA, Fan VS, et al. Improved Analgesia, Sedation, and Delirium Protocol Associated with Decreased Duration of Delirium and Mechanical Ventilation. *Ann Am Thorac Soc*. 2014;11(3):367-374. doi:10.1513/AnnalsATS.201306-210OC
40. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med*. 1998;158(16):1789-1795. doi:10.1001/archinte.158.16.1789
41. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). *Br J Addict*. 1989;84(11):1353-1357. doi:10.1111/j.1360-0443.1989.tb00737.x
42. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med*. 2001;29(7):1370-1379.
43. Mitasova A, Kostalova M, Bednarik J, et al. Poststroke delirium incidence and outcomes: Validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)\*. *Crit Care Med*. 2012;40(2):484-490. doi:10.1097/CCM.0b013e318232da12
44. Inouye SK. Clarifying Confusion: The Confusion Assessment Method: A New Method for Detection of Delirium. *Ann Intern Med*. 1990;113(12):941. doi:10.7326/0003-4819-113-12-941
45. Carin-Levy G, Mead GE, Nicol K, Rush R, van Wijck F. Delirium in acute stroke: screening tools, incidence rates and predictors: a systematic review. *J Neurol*. 2012;259(8):1590-1599. doi:10.1007/s00415-011-6383-4
46. McManus J, Pathansali R, Stewart R, Macdonald A, Jackson S. Delirium post-stroke. *Age Ageing*. 2007;36(6):613-618. doi:10.1093/ageing/afm140
47. Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: A randomized, placebo-controlled trial. *Int J Geriatr Psychiatry*. 2011;26(7):687-694. doi:10.1002/gps.2582
48. Campbell AM, Axon DR, Martin JR, Slack MK, Mollon L, Lee JK. Melatonin for the prevention of postoperative delirium in older adults: a systematic review and meta-analysis. *BMC Geriatr*. 2019;19(1):272. doi:10.1186/s12877-019-1297-6
49. Keen JC, Brown D. Psychostimulants and delirium in patients receiving palliative care. *Palliat Support Care*. 2004;2(2):199-202. doi:10.1017/S147895150404026X

50. Lodewijckx E, Debain A, Lieten S, Bravenboer B, Mets T. Pharmacologic Treatment for Hypoactive Delirium in Adult Patients: A Brief Report of the Literature. *J Am Med Dir Assoc*. 2021;22(6):1313-1316.e2. doi:10.1016/j.jamda.2020.12.037
51. Eskildsen MA. Use of Modafinil in Two Patients with Hypoactive Delirium. :2.
52. Tampi RR, Tampi DJ, Ghori AK. Acetylcholinesterase Inhibitors for Delirium in Older Adults. *Am J Alzheimers Dis Dementiasr*. 2016;31(4):305-310. doi:10.1177/1533317515619034
53. Tabet N, Howard R. Pharmacological treatment for the prevention of delirium: review of current evidence. *Int J Geriatr Psychiatry*. 2009;24(10):1037-1044. doi:10.1002/gps.2220
54. Inouye SK, Marcantonio ER, Metzger ED. Doing Damage in Delirium: The Hazards of Antipsychotic Treatment in Elderly Persons. *Lancet Psychiatry*. 2014;1(4):312-315. doi:10.1016/S2215-0366(14)70263-9
55. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: A review of the empirical literature. *Palliat Support Care*. 2005;3(3):227-237. doi:10.1017/S1478951505050352
56. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. *Nat Rev Neurosci*. 2006;7(6):492-500. doi:10.1038/nrn1926
57. Huo Z, Lin J, Bat BKK, Chan TK, Yip BHK, Tsoi KKF. Cost-effectiveness of pharmacological therapies for people with Alzheimer's disease and other dementias: a systematic review and meta-analysis. *Cost Eff Resour Alloc CE*. 2022;20(1):19. doi:10.1186/s12962-022-00354-3
58. Rosenheck RA, Leslie DL, Sindelar JL, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. *Arch Gen Psychiatry*. 2007;64(11):1259-1268. doi:10.1001/archpsyc.64.11.1259
59. Oh ES, Needham DM, Nikoie R, et al. Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review. *Ann Intern Med*. 2019;171(7):474-484. doi:10.7326/M19-1859
60. Nikoie R, Neufeld KJ, Oh ES, et al. Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. *Ann Intern Med*. 2019;171(7):485-495. doi:10.7326/M19-1860
61. Almeida TML de, Azevedo LCP de, Nosé PMG, Freitas FGR de, Machado FR. Risk factors for agitation in critically ill patients. *Rev Bras Ter Intensiva*. 2016;28(4). doi:10.5935/0103-507X.20160074
62. Mattappalil A, Mergenhagen KA. Neurotoxicity with Antimicrobials in the Elderly: A Review. *Clin Ther*. 2014;36(11):1489-1511.e4. doi:10.1016/j.clinthera.2014.09.020
63. Mandell LA, Niederman MS. Aspiration Pneumonia. *N Engl J Med*. 2019;380(7):651-663. doi:10.1056/NEJMra1714562
64. Dasgupta M, Brymer C, Elsayed S. Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study. *Arch Gerontol Geriatr*. 2017;72:127-134. doi:10.1016/j.archger.2017.05.010
65. Latuga NM, Grant PC, Levy K, Luczkiewicz DL. Treatment of Positive Urine Cultures at End-of-Life and the Effect on Terminal Delirium Management. *Am J Hosp Palliat Care*. Published online December 10, 2021:10499091211057848. doi:10.1177/10499091211057848
66. Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. *J Gerontol A Biol Sci Med Sci*. 2008;63(7):764-772.
67. Schor JD, Levkoff SE, Lipsitz LA, et al. Risk Factors for Delirium in Hospitalized Elderly. *JAMA*. 1992;267(6):5.

68. McCusker J, Cole MG, Dendukuri N, Belzile E. Does delirium increase hospital stay? *J Am Geriatr Soc*. 2003;51(11):1539-1546. doi:10.1046/j.1532-5415.2003.51509.x
69. Guillory J, Fitz-Gerald C, Banik A, et al. Comparison of hospital course and outcome in hospital-acquired vs pre-existing delirium. *Ann Clin Psychiatry Off J Am Acad Clin Psychiatr*. 2021;33(1):35-44. doi:10.12788/acp.0021

## Figures

Figure 1. Study Design Flowchart





## Tables

**Table 1. Demographic, clinical characteristics, and health outcomes for the study cohort according to patients who did not develop delirium or who developed delirium 48 hours or more after admission.** Patients assessed indicate the number of patients for whom data was potentially available for the characteristics depicted in the relevant row. Costs were determined from a hospital administrative database and can only be reported in relative units, as per hospital administrative policy.

	Patients who did not develop delirium		Patients who developed delirium		p-value*
	Patients assessed	# patients (%)	Patients assessed	# patients (%)	
<b>Delirium development</b>		1239 (72.5% of cohort)		471 (27.5% of cohort)	n/a
Time to delirium development, days, median (IQR)	1239	n/a	471	5.65 (3.29, 10.54)	n/a
Num of delirious days, median (IQR)	1239	n/a	471	3 (2, 7)	n/a
<b>Demographics</b>					
Age, median (IQR)	1239	66.95 (56.12, 77.19)	471	72.28 (61.49, 81.87)	<0.0001
Female sex, n (%)	1239	588 (47.46%)	471	203 (43.10%)	0.11
Married, n (%)	1179	642 (54.45%)	435	211 (48.51%)	0.03
English speaker, n (%)	1239	1073 (86.60%)	471	400 (84.93%)	0.37
Latinx ethnicity, n (%)	1131	78 (6.90%)	410	32 (7.80%)	0.54
<b>Race, n (%)</b>					
White	1238	932 (75.28%)	471	356 (75.58%)	0.98
Black		100 (8.08%)		37 (7.86%)	
Other		206 (16.64%)		78 (16.56%)	
<b>Insurance Payer, n (%)</b>					
Commercial	1239	368 (29.70%)	471	75 (15.92%)	<0.0001
Medicaid		157 (12.67%)		72 (15.29%)	
Medicare		683 (55.13%)		313 (66.45%)	
Other		31 (2.50%)		11 (2.34%)	
<b>Baseline characteristics</b>					
Visual impairment at baseline, n (%)	1193	978 (81.98%)	436	372 (85.32%)	0.11
Hearing impairment at baseline, n (%)	1137	575 (50.57%)	447	314 (70.25%)	<0.0001
Denture use at baseline, n (%)	1239	126 (10.17%)	471	60 (12.74%)	0.13
Memory impairment at baseline, n (%)	403	108 (26.80%)	117	55 (47.01%)	<0.0001
No. dependent ADLs, median (IQR)	1239	1.0 (0, 3)	471	2.0 (0, 5)	<0.0001
Ever smoker, n (%)	1160	202 (17.41%)	364	73 (20.05%)	0.25
Potentially hazardous alcohol use, n (%)	218	71 (32.57%)	48	23 (47.92%)	0.04

<b>Clinical characteristics</b>					
Intracranial hemorrhage, n (%)	1239	406 (32.77%)	471	243 (51.59%)	<0.0001
Ischemic stroke, n (%)	1239	787 (63.52%)	471	233 (49.47%)	<0.0001
NIHSS (ischemic stroke patients only), median (IQR)	545	3 (1, 8)	164	12 (5, 18)	<0.0001
tPA received, n (%)	1239	77 (6.21%)	471	49 (10.40%)	0.003
Neurovascular intervention (within first 48hrs for ischemic stroke patients), n (%)	787	50 (6.35%)	233	34 (14.59%)	<0.0001
ICU (within first 48hrs), n (%)	1239	544 (43.91%)	471	383 (81.32%)	<0.0001
Ventilator (within first 48hrs), n (%)	1239	171 (13.80%)	471	134 (28.45%)	<0.0001
Restraints (within first 48hrs), n (%)	1239	175 (14.12%)	471	238 (50.53%)	<0.0001
Urinary catheter (within first 48hrs), n (%)	1239	426 (34.38%)	471	323 (68.58%)	<0.0001
<b>Clinical Outcomes</b>					
LOS, median (IQR)	1239	4.94 (3.26-8.00)	471	13.66 (8.01-21.32)	<0.0001
30-day readmissions, n (%)	1239	222 (17.92%)	471	109 (23.14%)	0.01
Total cost, \$/constant, mean	1236	2744	470	5686	<0.0001
<b>Discharge disposition</b>					
Discharge to home	1239	691 (55.77%)	471	53 (11.25%)	<0.0001
SNF/Rehab/LTC		471 (38.01%)		367 (77.92%)	
In-hospital death		41 (3.31%)		26 (5.52%)	
Hospice		22 (1.78%)		17 (3.61%)	
Other		14 (1.13%)		8 (1.70%)	

\* Rank-sum test was used for continuous variables and Chi-square test or Fisher exact test were used for categorical variables.

**Table 2. Comparison of medication exposures within the first 48 hours between non-delirious and delirious patients.**

	<b>Non-delirious # patients=1239</b>	<b>Delirious # patients=471</b>	<b>Risk Ratio [95% CI]</b>	<b>p-value*</b>
Antipsychotics (all)	83 (6.70%)	102 (21.66%)	3.23 [2.37, 4.40]	<0.0001
Typical Antipsychotics	42 (3.39%)	66 (14.01%)	4.13 [2.77, 6.17]	<0.0001
Atypical Antipsychotics	52 (4.20%)	62 (13.16%)	3.14 [2.14, 4.60]	<0.0001
Sedatives	132 (10.65%)	121 (25.69%)	2.41 [1.84, 3.15]	<0.0001
Cholinesterase inhibitors	17 (1.37%)	14 (2.97%)	2.17 [1.06, 4.43]	0.03
Antimicrobials	261 (21.07%)	166 (35.24%)	1.67 [1.34, 2.09]	<0.0001
Opiates	380 (30.67%)	226 (47.98%)	1.56 [1.29, 1.90]	<0.0001
Antiepileptic	439 (35.43%)	235 (49.89%)	1.41 [1.16, 1.70]	<0.0001
Parkinson's Medications	17 (1.37%)	8 (1.70%)	1.24 [0.53, 2.89]	0.62
Steroids	117 (9.44%)	54 (11.46%)	1.21 [0.86, 1.70]	0.21
Benzodiazepines	294 (23.73%)	120 (25.48%)	1.07 [0.85, 1.36]	0.45
Anticholinergics	70 (5.65%)	28 (5.94%)	1.05 [0.67, 1.65]	0.81
Antiemetic	319 (25.75%)	123 (26.11%)	1.01 [0.80, 1.28]	0.88
Sleep aids	142 (11.46%)	50 (10.62%)	0.93 [0.66, 1.30]	0.62
Stimulant	21 (1.69%)	7 (1.49%)	0.88 [0.37, 2.08]	0.76
Mood stabilizer	292 (23.57%)	96 (20.38%)	0.86 [0.67, 1.11]	0.16
Muscle relaxants	21 (1.69%)	4 (0.85%)	0.50 [0.17, 1.47]	0.26

\* Chi-square test or Fisher exact test were used for categorical variables.

**Table 3. Multivariable model testing associations of medication classes associated with the development of delirium.**

	<b>Relative risk</b>	<b>95% CI</b>	<b>p-value*</b>
Patient's age	1.03	1.02, 1.04	<0.0001
Female	0.73	0.58, 0.92	0.01
Hemorrhage	1.44	1.07, 1.93	0.02
Ventilator used within first 48 hours	1.06	0.55, 2.04	0.87
Typical antipsychotic used within first 48 hours	2.96	1.90, 4.63	<0.0001
Atypical antipsychotic used within first 48 hours	2.29	1.47, 3.55	0.0002
Sedative used within first 48 hours	2.13	1.06, 4.28	0.03
Cholinesterase inhibitor used within first 48 hours	1.38	0.62, 3.09	0.43
Antimicrobial used within first 48 hours	1.47	1.12, 1.93	0.006
Opiate used within first 48 hours	1.68	1.28, 2.21	0.0002
Antiepileptic used within first 48 hours	0.93	0.69, 1.25	0.63

**Table 4. Comparison of medications pre- and post-delirium identification for delirious patients only**

	<b>Pre-delirium (n=471)</b>	<b>Post-delirium (n=471)</b>	<b>Absolute Change (%)</b>	<b>p-value</b>
<b>Whether the medication was taken, n (%)</b>				
Antipsychotics (all)	192 (40.76%)	211 (44.80%)	+4.04%	0.07
Typical Antipsychotics	101 (21.44%)	65 (13.80%)	+7.64%	0.0007
Atypical Antipsychotics	156 (33.12%)	203 (43.10%)	+9.98%	<0.0001
Sedatives	140 (29.72%)	30 (6.37%)	-23.35%	<0.0001
Cholinesterase inhibitors	17 (3.61%)	20 (4.25%)	+0.64%	0.18
Antimicrobials	241 (51.17%)	208 (44.16%)	-7.01%	0.01
Opiates	270 (57.32%)	205 (43.52%)	-13.8%	<0.0001
Antiepileptic	259 (54.99%)	215 (45.65%)	-9.34%	<0.0001
Parkinson's Medications	11 (2.34%)	14 (2.97%)	+0.63 %	0.18
Steroids	83 (17.62%)	61 (12.95%)	-4.67%	0.005
Benzodiazepines	176 (37.37%)	93 (19.75%)	-17.62%	<0.0001
Anticholinergics	57 (12.10%)	51 (10.83%)	-1.27%	0.45
Antiemetic	183 (38.85%)	114 (24.20%)	-14.65%	<0.0001
Sleep aids	194 (41.19%)	263 (55.84%)	+14.65%	<0.0001
Stimulant	55 (11.68%)	76 (16.14%)	+4.46%	0.0004
Mood stabilizer	156 (33.12%)	181 (38.43%)	+5.31%	0.0007
Muscle relaxants	11 (2.34%)	16 (3.40%)	+1.06%	0.23

McNemar's test was used to compare agreement of medication used before and after delirium.

## **Supplementary Material (Tables S1-S3)**

### **Associations between in-hospital medications and delirium in patients with stroke**

Sophia L. Ryan MD,<sup>1,2</sup> Xiu Liu MS,<sup>1,3</sup> Vanessa McKenna RN,<sup>1</sup> Manohar Ghanta MS,<sup>1</sup> Carlos Muniz MD

MSc,<sup>1,4</sup> Rachel Renwick, PharmD,<sup>1</sup> M. Brandon Westover MD PhD,<sup>1</sup> Eyal Y. Kimchi MD PhD<sup>1</sup>

1. Department of Neurology, Massachusetts General Hospital
2. Department of Neurology, Mount Sinai Medical Center
3. Lawrence Center for Quality and Safety, Massachusetts General Hospital
4. Department of Neurology, SUNY Upstate Medical University

**Table S1. Medications included in each class**

Acetylcholinesterase Inhibitors & memantine	donepezil, galantamine, memantine, memantine/donepezil, physostigmine salicylate, rivastigmine, rivastigmine tartrate
Anticholinergic	atropine sulfate, belladonna, benzotropine mesylate, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, clidinium, cyproheptadine, darifenacin hydrobromide, dexbrompheniramine, dexchlorpheniramine, dicyclomine, dimenhydrinate, diphenhydramine, diphenoxylate/atropine, disopyramide phosphate, doxylamine, fesoterodine fumarate, flavoxate, glycopyrrolate, glycopyrrolate/formoterol, homatropine, hydroxyzine, hyoscyamine sulfate, ipratropium bromide, ipratropium/albuterol sulfate, meclizine, methscopolamine, opium/belladonna alkaloids, oxybutynin, oxybutynin chloride, propantheline bromide, pyrilamine, scopolamine, solifenacin succinate, tolterodine tartrate, trihexyphenidyl, triprolidine, trospium chloride
Antiemetic	aprepitant, fosaprepitant, metoclopramide, ondansetron, palonosetron, prochlorperazine, promethazine
Antiepileptic	brivaracetam, carbamazepine, divalproex sodium, eslicarbazepine acetate, ethambutol, ethambutol, ethosuximide, felbamate, fosphenytoin, gabapentin, , lacosamide, lamictal, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, tiagabine, topiramate, valproate, valproic acid, vigabatrin, zonisamide
Antimicrobial	abacavir sulfate, abacavir sulfate/lamivudine, abacavir/dolutegravir/lamivudine, acyclovir, albendazole, amikacin, amoxicillin, amphotericin, ampicillin, atazanavir sulfate, atazanavir sulfate/cobicistat, atovaquone, atovaquone/proguanil, azithromycin, aztreonam, bacitracin, bacitracin/polymyxin b sulfate, bedaquiline fumarate, bictegrovir, caspofungin, cefadroxil, cefazolin, cefepime, ceftazidime, ceftriaxone, cefuroxime, cefuroxime axetil, ceftazidime, ceftazidime, ceftolozane, ceftriaxone, cefuroxime, cefuroxime axetil, cephalexin, chloroquine phosphate, cidofovir, ciprofloxacin, ciprofloxacin/dexameth, ciprofloxacin in 5 % dextrose, clarithromycin, clindamycin, clotrimazole, colistin, cycloserine, dapsone, daptomycin, darunavir, demeclocycline, dicloxacillin sodium, dolutegravir sodium, doravirine, doxycycline, efavirenz, efavirenz/emtricit/tenofovr df, efinaconazole, elbasvir/grazoprevir, elviteg/cob/emtri/tenof alafen, elviteg/cob/emtri/tenofo disop, emtricitab/rilpiviri/tenof ala, emtricitabine, emtricitabine/tenofof alafenam, emtricitabine/tenofovir (tdf), entecavir, ertapenem, erythromycin, etravirine, famciclovir, fluconazole, flucytosine, foscarnet, fosfomycin tromethamine, ganciclovir, gentamicin, gentian violet, imipenem, isavuconazonium sulfate, isoniazid, itraconazole, ivermectin, ketoconazole, lamivudine, lamivudine/zidovudine, ledipasvir/sofosbuvir, levofloxacin, linezolid, lopinavir/ritonavir, mafenide, maraviroc, meropenem, methenamine hippurate, metronidazole, micafungin, miconazole nitrate, miltefosine, minocycline, moxifloxacin, mupirocin, nafcillin, natamycin, neomycin sulf/bacitracin/poly, neomycin sulfate, neomycin/bacitracin/polymyxinb, neomycin/polymyxin b/dexametha, neomycin/polymyxin b/hydrocort, nevirapine, nitrofurantoin, nystatin, ofloxacin, oseltamivir phosphate, oxacillin, paromomycin sulfate, penicillin, penicillin g benzathine, penicillin v potassium, pentamidine, permethrin, piperacillin, piperacillin sodium/tazobactam, polymyxin, polymyxin b sulf/trimethoprim, posaconazole, praziquantel, pyrazinamide, pyrimethamine, quinidine sulfate, raltegravir potassium, ribavirin, rifabutin, rifampin, rifapentine, rifaximin, rilpivirine, ritonavir, silver sulfadiazine, sofosbuvir/velpatasvir, sulfacetamide sodium, sulfadiazine, sulfamethoxazole/trimethoprim, tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, terbinafine, terconazole, tetracycline, tobramycin, tobramycin/dexamethasone, tolnaftate, trimethoprim, valacyclovir, valganciclovir, vancomycin, voriconazole
Antipsychotics: Atypical	aripiprazole, asenapine maleate, fluphenazine, lurasidone, olanzapine, paliperidone, pimozide, quetiapine fumarate, risperidone, ziprasidone
Antipsychotics: Typical	chlorpromazine, chlorpromazine, clozapine, fluvoxamine maleate, haloperidol, haloperidol decanoate, haloperidol lactate, loxapine, perphenazine, thioridazine,

	trifluoperazine
Benzodiazepine	alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate dipotassium, diazepam, flurazepam, lorazepam, midazolam, oxazepam, temazepam, triazolam
Mood/Stabilizer	amitriptyline, amoxapine, bupropion, buspirone, cariprazine, citalopram hydrobromide, clomipramine, desipramine, desvenlafaxine, desvenlafaxine succinate, doxepin, duloxetine, escitalopram oxalate, fluoxetine, imipramine, lithium carbonate, lithium citrate, milnacipran, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine sulfate, protriptyline, sertraline, tranylcypromine sulfate, trimipramine, venlafaxine, vilazodone, vortioxetine hydrobromide
Muscle Relaxant	baclofen, carisoprodol, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine, tizanidine
Opiate	acetaminophen with codeine, buprenorphine, buprenorphine/naloxone, codeine phosphate/guaifenesin, dextromethorphan/quinidine, dextromethorphan polistirex, diphenoxylate/atropine, fentanyl, hydrocodone/acetaminophen, hydromorphone, meperidine, methadone, morphine, nalbuphine, opium tincture, opium/belladonna alkaloids, oxycodone, oxycodone/acetaminophen, tramadol
Parkinson	bromocriptine mesylate, cabergoline, carbidopa, carbidopa/levodopa, carbidopa/levodopa/entacapone, entacapone, pimavanserin tartrate, pramipexole, rasagiline mesylate, ropinirole, rotigotine, selegiline, tolcapone
Sedative	dexmedetomidine, etomidate, ketamine, pentobarbital, propofol, xenon
Sleep Aid	eszopiclone, melatonin, tasimelteon, trazodone, zaleplon, zolpidem tartrate
Steroid	betamethasone valerate, betamethasone/propylene glycol, dexamethasone, fludrocortisone acetate, flucinolone acetonide, fluticasone furoate, fluticasone propionate, fluticasone/salmeterol, fluticasone/vilanterol, hydrocortisone, methylprednisolone, mometasone furoate, mometasone/formoterol, prednisolone acetate, prednisone, triamcinolone acetonide
Stimulant	amantadine, armodafinil, desloratadine/pseudoephedrine, dexmethylphenidate, dextroamphetamine sulfate, dextroamphetamine/amphetamine, ephedrine, lisdexamfetamine dimesylate, methylphenidate, modafinil, pseudoephedrine



**Table S2. Demographic, clinical characteristics, and health outcomes for the study cohort according to patients who were and were not assessed for delirium.**

	Patients not assessed for delirium		Patients assessed for delirium		P-value*
	Patients with data	# patients (%)	Patients with data	# patients (%)	
<b>Demographics</b>					
Age, median (IQR)	1180	66.50 (55.06, 78.45)	1710	68.45 (57.70, 79.03)	0.0052
Female sex, n (%)	1180	545 (46.19%)	1710	791 (46.26%)	0.9700
English speaker, n (%)	1175	1043 (88.77%)	1704	1470 (86.27%)	0.0479
Latinx ethnicity, n (%)	1072	71 (6.62%)	1551	110 (7.09%)	0.6413
<b>Race, n (%)</b>					
White	1107	915 (82.66%)	1601	1296 (80.95%)	0.2594
Black	1107	72 (6.50%)	1601	135 (8.43%)	0.0634
Other	1107	120 (10.84%)	1601	170 (10.62%)	0.8544
<b>Baseline characteristics</b>					
Visual impairment at baseline, n (%)	1114	869 (78.01%)	1629	1350 (82.87%)	0.0015
Hearing impairment at baseline, n (%)	1046	486 (46.46%)	1584	889 (56.12%)	<0.0001
Denture use at baseline, n (%)	1180	87 (7.37%)	1710	186 (10.88%)	0.0015
Memory impairment at baseline, n (%)	310	115 (37.10%)	520	163 (31.35%)	0.0895
No. dependent ADLs, median (IQR)	1180	1.00 (0.00, 3.00)	1710	1.00 (0.00, 3.00)	0.3531
Ever smoker, n (%)	1072	170 (15.86%)	1524	275 (18.04%)	0.1456
Potentially hazardous alcohol use, n (%)	132	56 (42.42%)	266	94 (35.34%)	0.1696
<b>Clinical characteristics</b>					
Intracranial hemorrhage, n (%)	1180	472 (40.00%)	1710	649 (37.95%)	0.2670
Ischemic stroke, n (%)	1180	642 (54.41%)	1710	1020 (59.65%)	0.0051
NIHSS (ischemic stroke patients only), median (IQR)	425	3.00 (1.00, 9.00)	765	4.00 (1.00, 11.00)	0.0554
tPA received, n (%)	1180	61 (5.17%)	1710	126 (7.37%)	0.0182
Neurovascular intervention (within first 48hrs for ischemic stroke patients), n (%)	1180	32 (2.71%)	1710	87 (5.09%)	0.0016
ICU (within first 48hrs), n (%)	1180	530 (44.92%)	1710	927 (54.21%)	<0.0001
Ventilator (within first 48hrs), n (%)	1180	162 (13.73%)	1710	305 (17.84%)	0.0032
Restraints (within first 48hrs), n (%)	1180	188 (15.93%)	1710	413 (24.15%)	0.0000
Urinary catheter (within first 48hrs), n (%)	1180	474 (40.17%)	1710	749 (43.80%)	0.0521
<b>Clinical Outcomes</b>					

LOS, median (IQR)	1180	4.46 (3.04, 7.40)	1710	6.26 (3.83, 12.39)	<0.0001
30-day readmissions, n (%)	1180	190 (16.10%)	1710	331 (19.36%)	0.0253
<b>Discharge disposition</b>					
Discharge to home	1180	433 (36.69%)	1710	462 (27.02%)	<0.0001
SNF/Rehab/LTC	1180	544 (46.10%)	1710	966 (56.49%)	<0.0001
In-hospital death	1180	87 (7.37%)	1710	67 (3.92%)	<0.0001
Hospice	1180	41 (3.47%)	1710	39 (2.28%)	0.0545

\* Rank-sum test was used for continuous variables and Chi-square test or Fisher exact test were used for categorical variables.

**Table S3.** Comparison of medications used within the first 48 hours, stratified by patients' ventilator status and whether they developed delirium. Antipsych = Antipsychotic

	Non-ventilated (patients=1405)			Ventilated (patients=305)		
	Non-delirium (patients=1068)	Delirium (patients=337)	p- value*	Non-delirium (patients=171)	Delirium (patients=134)	p- value*
Number of medications received during the first 48h, median (IQR)	16 (12, 21)	21 (16, 26)	<0.0001	27 (21, 32)	31 (27, 35)	<0.0001
<b>Whether the medication was taken within the first 48 hours, n (%)</b>						
Antipsychotics (all)	62 (5.81%)	79 (23.44%)	<0.0001	21 (12.28%)	23 (17.16%)	0.23
Typical Antipsych	30 (2.81%)	47 (13.95%)	<0.0001	12 (7.02%)	19 (14.18%)	0.04
Atypical Antipsych	39 (3.65%)	48 (14.24%)	<0.0001	13 (7.60%)	14 (10.45%)	0.39
Sedatives	0 (0.00%)	1 (0.30%)	0.24	132 (77.19%)	120 (89.55%)	0.005
Cholinesterase inhibitors	16 (1.50%)	11 (3.26%)	0.04	1 (0.58%)	3 (2.24%)	0.32
Antimicrobials	183 (17.13%)	89 (26.41%)	0.0002	78 (45.61%)	77 (57.46%)	0.04
Opiates	272 (25.47%)	119 (35.31%)	0.0004	108 (63.16%)	107 (79.85%)	0.002
Antiepileptic	336 (31.46%)	144 (42.73%)	0.0001	103 (60.23%)	91 (67.91%)	0.17
Parkinson's Medications	13 (1.22%)	8 (2.37%)	0.13	4 (2.34%)	0 (0.00%)	0.14
Steroids	103 (9.64%)	29 (8.61%)	0.57	14 (8.19%)	25 (18.66%)	0.007
Benzodiazepines	248 (23.22%)	84 (24.93%)	0.52	46 (26.90%)	36 (26.87%)	0.99
Anticholinergics	61 (5.71%)	18 (5.34%)	0.80	9 (5.26%)	10 (7.46%)	0.43
Antiemetic	270 (25.28%)	93 (27.60%)	0.40	49 (28.65%)	30 (22.39%)	0.22
Sleep aids	132 (12.36%)	44 (13.06%)	0.74	10 (5.85%)	6 (4.48%)	0.59
Stimulant	19 (1.78%)	6 (1.78%)	0.99	2 (1.17%)	1 (0.75%)	1.00
Mood stabilizer	274 (25.66%)	84 (24.93%)	0.79	18 (10.53%)	12 (8.96%)	0.65
Muscle relaxants	20 (1.87%)	2 (0.59%)	0.13	1 (0.58%)	2 (1.49%)	0.58

\* Rank-sum test was used for continuous variables (number of medications), and Chi-square test or Fisher exact test were used for categorical variables.

Figure 1

